Skip to main content
    S

    Sonoma Pharmaceuticals Inc (SNOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.88
    -0.21 (-19.25%)

    Market Cap: $5.52M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Sonoma Pharmaceuticals Inc (SNOA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Sonoma Pharmaceuticals reported revenue of $19.53M for the fiscal year ended Mar 31, 2026, up 36.7% from the year before. That year, net income was -$3.17M with a net margin of -16.3%, operating cash flow was -$3.93M and free cash flow was -$4.13M. The quarter ended Sep 30, 2026 had revenue of $7.17M and net income of -$66.00K.

    Revenue and Margins

    The operating margin was -12.6% in the fiscal year ended Mar 2026, the highest of the 9 years shown with an operating margin. Over the 9 years to Mar 2026, revenue grew from $12.82M, a compound annual rate of 4.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$19.53M+36.7%38.0%-12.6%-16.3%
    Mar 2025$14.29M+12.2%38.2%-26.0%-24.2%
    Mar 2024$12.73M-4.0%37.3%-36.9%-38.0%
    Mar 2023$13.27M+5.1%33.7%-34.4%-38.8%
    Mar 2022$12.63M-32.2%31.6%-46.6%-40.3%
    Mar 2021$18.63M+3.9%35.2%-18.5%-21.2%
    Mar 2020$17.93M-52.7%45.3%-41.2%-18.5%
    Mar 2019$37.94M+127.8%46.8%-29.7%-31.1%
    Mar 2018$16.66M+29.9%43.9%-85.2%-86.0%
    Mar 2017$12.82MN/A44.2%-101.2%72.3%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$19.53M$14.29M$12.73M$13.27M$12.63M$18.63M$17.93M$37.94M$16.66M$12.82M
    Cost of revenue$12.11M$8.82M$7.99M$8.79M$8.63M$12.07M$9.81M$20.18M$9.35M$7.16M
    Gross profit$7.42M$5.46M$4.75M$4.48M$3.99M$6.56M$8.12M$17.76M$7.31M$5.67M
    Research and development$2.27M$1.81M$1.87M$207.00K$125.00K$555.00K$1.34M$1.52M$1.57M$1.58M
    Operating income-$2.46M-$3.71M-$4.70M-$4.57M-$5.89M-$3.45M-$7.39M-$11.26M-$14.19M-$12.97M
    Net income-$3.17M-$3.46M-$4.83M-$5.15M-$5.09M-$3.95M-$3.31M-$11.80M-$14.33M$9.27M
    EBITDAN/A-$2.77MN/AN/AN/AN/A-$3.27M-$11.04M-$14.01M-$12.73M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$7.17M$6.41M$5.56M$4.35M$5.60M$4.01M$3.75M$3.56M$3.58M$3.39M$3.44M$3.14M
    Gross profit$2.81M$2.58M$2.18M$1.65M$2.12M$1.46M$1.53M$1.27M$1.36M$1.31M$1.09M$1.46M
    Operating income$290.00K-$40.00K-$351.00K-$678.00K-$337.00K-$1.09M-$656.00K-$1.03M-$850.00K-$1.17M-$1.41M-$844.00K
    Net income-$66.00K-$330.00K-$581.00K-$819.00K-$534.00K-$1.24M-$776.00K-$928.00K-$610.00K-$1.14M-$1.07M-$866.00K
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded short-term debt of $222.00K by $2.18M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$13.96M$13.69M$14.74M$16.23M$18.84M$14.99M$14.56M$14.45M$19.21M$25.46M
    Current assets$12.10M$12.65M$12.55M$13.80M$16.43M$12.98M$12.28M$12.50M$16.25M$22.64M
    Cash and equivalents$2.40M$5.37M$3.13M$3.82M$7.40M$4.22M$3.69M$3.69M$10.07M$17.46M
    Total liabilities$10.87M$9.28M$8.60M$8.25M$10.15M$9.62M$8.94M$3.96M$3.88M$4.03M
    Short-term debt$222.00K$220.00K$323.00K$431.00K$808.00K$596.00K$481.00K$463.00K$377.00K$197.00K
    Long-term debtN/AN/AN/AN/AN/A$1.31M$0$12.00K$32.00K$45.00K
    Shareholder equity$3.10M$4.41M$6.14M$7.98M$8.70M$5.36M$5.62M$10.49M$15.33M$21.43M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$17.10M$18.11M$13.96M$13.62M$13.86M$14.59M$13.69M$13.67M$13.69M$13.67M$14.74M$14.62M
    Total liabilities$10.49M$11.51M$10.87M$10.19M$10.07M$10.54M$9.28M$8.80M$8.33M$8.70M$8.60M$7.93M
    Cash and equivalents$4.61M$5.34M$2.40M$2.56M$3.04M$3.60M$5.37M$5.24M$4.08M$2.59M$3.13M$2.41M
    Shareholder equity$6.61M$6.59M$3.10M$3.43M$3.79M$4.06M$4.41M$4.87M$5.35M$4.97M$6.14M$6.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$3.93M-$88.00K-$2.40M-$6.15M-$4.25M-$3.38M-$4.59M-$11.72M-$12.44M-$26.64M
    Capital expenditures$192.00K$80.00K$2.00K$269.00K$137.00K$179.00K$206.00K$100.00K$187.00K$394.00K
    Free cash flow-$4.13M-$168.00K-$2.40M-$6.42M-$4.38M-$3.56M-$4.80M-$11.82M-$12.63M-$27.03M
    Investing cash flow-$192.00K-$80.00K-$2.00K-$258.00K-$99.00K$388.00K$3.64M-$131.00K-$201.00K$18.22M
    Financing cash flow$477.00K$3.03M$1.68M$2.49M$7.40M$3.31M$1.03M$5.49M$5.24M-$32.00K
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$736.00K-$649.00K-$519.00K-$764.00K-$635.00K-$2.02M-$95.00K$565.00K$354.00K-$912.00K$152.00K-$1.10M
    Capital expenditures$42.00K$2.00K$29.00K$47.00K$10.00K$106.00K$47.00K$2.00K$26.00K$5.00K$18.00K$1.00K
    Free cash flow-$778.00K-$651.00K-$548.00K-$811.00K-$645.00K-$2.12M-$142.00K$563.00K$328.00K-$917.00K$134.00K-$1.10M
    Last 12 quarters

    Frequently Asked Questions About SNOA

    What is Sonoma Pharmaceuticals' annual revenue?

    Sonoma Pharmaceuticals reported revenue of $19.53M for the fiscal year ended Mar 31, 2026.

    How fast is Sonoma Pharmaceuticals' revenue growing?

    Revenue was up 36.7% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 13.7%.

    Is Sonoma Pharmaceuticals profitable?

    No. Sonoma Pharmaceuticals reported net income of -$3.17M for the fiscal year ended Mar 31, 2026, with a net margin of -16.3%.

    How much free cash flow does SNOA generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$3.93M minus capital expenditures of $192.00K produced free cash flow of -$4.13M.

    How much debt does Sonoma Pharmaceuticals have?

    The balance sheet dated Mar 31, 2026 reported short-term debt of $222.00K and cash and equivalents of $2.40M.